EXACT Sciences Corporation (EXAS) - Total Liabilities
Based on the latest financial reports, EXACT Sciences Corporation (EXAS) has total liabilities worth $3.46 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore EXACT Sciences Corporation (EXAS) investment intensity to see how much of total assets are deployed in long-term investments.
EXACT Sciences Corporation - Total Liabilities Trend (1998–2025)
This chart illustrates how EXACT Sciences Corporation's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see EXACT Sciences Corporation (EXAS) total assets.
EXACT Sciences Corporation Competitors by Total Liabilities
The table below lists competitors of EXACT Sciences Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Curtiss-Wright Corporation
NYSE:CW
|
USA | $2.69 Billion |
|
Fubon Financial Holding Co Ltd Pref
TW:2881A
|
Taiwan | NT$11.88 Trillion |
|
Shanxi Xinghuacun Fen Wine Factory Co Ltd
SHG:600809
|
China | CN¥25.05 Billion |
|
EDP - Energias de Portugal S.A.
LS:EDP
|
Portugal | €39.09 Billion |
|
Bank of Shanghai Co Ltd
SHG:601229
|
China | CN¥3.12 Trillion |
|
Reliance Steel & Aluminum Co
NYSE:RS
|
USA | $3.68 Billion |
|
Kyocera Corporation
F:KYRA
|
Germany | €1.20 Trillion |
|
Coeur Mining Inc
NYSE:CDE
|
USA | $4.79 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down EXACT Sciences Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See EXAS net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how EXACT Sciences Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for EXACT Sciences Corporation (1998–2025)
The table below shows the annual total liabilities of EXACT Sciences Corporation from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.46 Billion | -1.88% |
| 2024-12-31 | $3.53 Billion | +6.01% |
| 2023-12-31 | $3.33 Billion | +4.47% |
| 2022-12-31 | $3.18 Billion | -3.44% |
| 2021-12-31 | $3.30 Billion | +22.60% |
| 2020-12-31 | $2.69 Billion | +120.87% |
| 2019-12-31 | $1.22 Billion | +44.44% |
| 2018-12-31 | $843.08 Million | +978.91% |
| 2017-12-31 | $78.14 Million | +87.19% |
| 2016-12-31 | $41.74 Million | +11.50% |
| 2015-12-31 | $37.44 Million | +65.37% |
| 2014-12-31 | $22.64 Million | +100.16% |
| 2013-12-31 | $11.31 Million | -16.36% |
| 2012-12-31 | $13.52 Million | +0.49% |
| 2011-12-31 | $13.46 Million | -19.71% |
| 2010-12-31 | $16.76 Million | -14.82% |
| 2009-12-31 | $19.68 Million | +136.18% |
| 2008-12-31 | $8.33 Million | +0.29% |
| 2007-12-31 | $8.31 Million | -6.77% |
| 2006-12-31 | $8.91 Million | -32.62% |
| 2005-12-31 | $13.22 Million | -27.05% |
| 2004-12-31 | $18.13 Million | -19.26% |
| 2003-12-31 | $22.45 Million | +91.30% |
| 2002-12-31 | $11.74 Million | +183.95% |
| 2001-12-31 | $4.13 Million | +204.22% |
| 2000-12-31 | $1.36 Million | +295.10% |
| 1999-12-31 | $343.89K | -16.12% |
| 1998-12-31 | $410.00K | -- |
About EXACT Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence S… Read more